BNT162b2 Protection against the Omicron Variant in Children and AdolescentsBNT162b2 아동 및 청소년의 오미크론 변이체에 대한 보호Original Article Published on 2022-03-302022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Adolescent age B.1.1.529 B.1.617.2 BNT162b2 caused center children circulation Control controls coronavirus coronavirus disease Critical death died dose Effectiveness enrolled hospital Hospitalization immune evasion laboratory-confirmed median interval Messenger RNA of BNT162b2 omicron Patient prevented protection provided reduced Result risk SARS-CoV-2 Support vaccination Vaccine variant [DOI] 10.1056/NEJMoa2202826 PMC 바로가기 [Article Type] Original Article
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in IsraelArticle Published on 2022-03-112022-11-16 Journal: Science (New York, N.y.) [Category] SARS, 변종, [키워드] acute respiratory syndrome B.1.617.2 BNT162b2 confidence interval coronavirus COVID-19 Delta delta variant Effectiveness examined household contact household transmission Immunity individual level Infection Messenger RNA reduce reduced SARS-CoV-2 second dose susceptibility Total Transmission transmission of SARS-CoV-2 vaccination Vaccine variant [DOI] 10.1126/science.abl4292 PMC 바로가기
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina노스캐롤라이나에서 9개월 동안의 Covid-19 백신의 효과Article Published on 2022-03-102022-09-11 Journal: The New England Journal of Medicine [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval Ad26 Ad26.COV2.S B.1.617.2 BNT162b2 caused coronavirus disease Coronavirus disease 2019 COV2.S Cox regression model death declining delta variant dominant dose Effectiveness elapsed first dose Hospitalization Immunity increase in Infection Messenger RNA Moderna mRNA mRNA vaccine mRNA-1273 North of BNT162b2 outcome Period Pfizer-BioNTech postvaccination preventing infection provided recipient reducing regimen risk summer System the United State two-dose regimen United States vaccination Vaccine variant Viral particles [DOI] 10.1056/NEJMoa2117128 PMC 바로가기 [Article Type] Article
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditisPoint of View Published on 2022-03-092022-10-30 Journal: Netherlands Heart Journal [Category] COVID-19, [키워드] adolescents and adults available data benefit Biomarkers cohort study Complication coronavirus 2019 disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA Vaccination COVID-19 pandemic COVID-19 vaccination Critical death disease course echocardiographic finding effective Follow-up greater highest incidence incidence rate Infectious disease majority male management Messenger RNA mRNA myocarditis Normalisation outcomes Patient Pericarditis potential risk Prospective receiving regulatory agency required resolution of symptom risk second dose shown Side effect vaccination vaccination against COVID-19 Vaccine viral spread [DOI] 10.1007/s12471-022-01677-9 PMC 바로가기 [Article Type] Point of View
Pandemic-response adenoviral vector and RNA vaccine manufacturing Research Published on 2022-03-022022-10-05 Journal: NPJ Vaccines [Category] 임상, [키워드] adenoviral vector Analysis baseline booster COVID-19 COVID-19 pandemic feasibility Global Sensitivity Analysis improvement Messenger RNA mRNA platform provide quantified Rapid resource risk RNA RNA vaccine vaccination Vaccine vaccine dose vaccine platform vaccine production Vaccines [DOI] 10.1038/s41541-022-00447-3 [Article Type] Research
Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in SingaporeObservational Study Published on 2022-03-012022-10-04 Journal: JAMA Network Open [Category] SARS, 임상, [키워드] 95% CI age BNT162b2 caused cerebral Characteristics clinical Clinical characteristics conducted diagnosed dose hospital Hospitalization immunisation incidence incidence rate individual Infection male median Messenger RNA Moderna mRNA mRNA-1273 mRNA-based mRNA-based SARS-CoV-2 vaccines Observational cohort study occur outcome patients hospitalized Perspective Pfizer-BioNTech positive serology Quantitative registry remained report SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly higher Singapore the median vaccination Vaccine Venous thrombosis [DOI] 10.1001/jamanetworkopen.2022.2940 PMC 바로가기 [Article Type] Observational Study
Effective viral vector response to SARS-CoV-2 booster vaccination in a patient with rheumatoid arthritis after initial ineffective response to messenger RNA vaccine메신저 RNA 백신에 대한 초기 비효과적인 반응 후 류마티스 관절염 환자에서 SARS-CoV-2 추가 백신 접종에 대한 효과적인 바이러스 벡터 반응Case Reports Published on 2022-03-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] MERS, 진단, [키워드] booster vaccination initial Messenger RNA Patient rheumatoid arthritis SARS-CoV-2 Vaccine Viral vector [DOI] 10.1002/art.41978 PMC 바로가기 [Article Type] Case Reports
Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 변이체에 대한 중화 항체 자연 감염 또는 예방 접종으로 유도: 체계적인 검토 및 통합 분석Article Published on 2022-03-012022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 변종, 진단, [키워드] (alpha (Beta) 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Alpha antibody Antibody titers average B.1.1.7 B.1.351 B.1.617.2 collected coronavirus coronavirus 2 eligibility criteria escaped evaluated fold Immunity induced infected individuals Infection Lineage Live virus Messenger RNA natural natural infection neutralization Neutralization assay Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers Neutralizing titer neutralizing titers P.1 platform Protein subunit reduction in reductions in respiratory review SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants searched serum severe acute respiratory syndrome Coronavirus significant reductions significantly titers vaccination Vaccine vaccinee vaccinees variant variants [DOI] 10.1093/cid/ciab646 PMC 바로가기 [Article Type] Article
Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients통합 멀티오믹스 및 in silico 분석은 경증 및 중증 COVID-19 환자에서 ARHGEF1 및 선별된 길항제의 역할을 밝혔습니다.Article Published on 2022-03-012022-09-11 Journal: Journal of cellular biochemistry [Category] SARS, 유전자 메커니즘, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis anticancer Antiviral ARHGEF1 association Biotechnology caused center co-expression co-expression network Compound computational tool computational tools coronavirus COVID-19 database DEGs determine differentially expressed gene Differentially expressed genes disease effective therapy ENhance enrichment expressed expression profile gene co-expression network Gene ontology group guanine identify in silico analysis In silico methods in vitro in vivo infected patients inherent Medicines messenger Messenger RNA Mild molecular molecular docking molecular dynamics MSI-DEGs nucleotide number of infected Ontology overlapping pathogenic pathway patients worldwide protein-protein interaction rapid increase required Research SARS-CoV-2 SARS-CoV-2 patients screened severe acute respiratory syndrome Coronavirus severe COVID-19 patient Severity of infection stratified target therapeutic drug therapeutic efficacy therapeutic target therapy virus [DOI] 10.1002/jcb.30213 PMC 바로가기 [Article Type] Article
Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents이전 SARS-CoV-2 감염, 연령 및 노쇠는 요양원 거주자의 6개월 백신 유도 항스파이크 항체 역가와 관련이 있습니다Article Published on 2022-03-012022-09-11 Journal: Journal of the American Medical Directors Associat [Category] MERS, SARS, 진단, 치료법, [키워드] 95% confidence interval ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age All participant All participants analyzed angiotensin Angiotensin-converting enzyme Anti-spike anti-spike antibody antibody Antibody Response Antibody titer Antibody titers BNT162b2 Clinical outcome clinical outcomes cohort study Comorbidity Comprehensive coronavirus correlated COVID-19 demonstrated determinant determinants Evidence evidence of examined female frailty home in vitro independent of Infection log-transformed Long-term care longitudinal longitudinal cohort study make up Messenger RNA morbidity morbidity and mortality naïve Neutralization assay neutralization capacity nucleocapsid Nursing nursing home nursing homes Older participant post vaccination RBD receptor Receptor binding domain resident respiratory risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2.0 Serum Neutralization setting severe acute respiratory syndrome Coronavirus significantly significantly lower the strongest timepoints titer vaccination Vaccine vulnerable population was performed [DOI] 10.1016/j.jamda.2021.12.001 PMC 바로가기 [Article Type] Article